Adocia SA · EURONEXT:ADOC

Adocia SA — Investor Presentation (January 2020)

32 slides from Adocia SA's investor presentation, January 2020

  1. Slide 1: Adocia Corporate Presentation January 2020

    Slide 1: Adocia Corporate Presentation January 2020

    ADOCIA CORPORATE PRESENTATION January 2020

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    DISCLAIMER This corporate presentation (the “Presentation”) has been prepared by ADOCIA (the “Company”) and is provided for information purposes only. It is not for promotional use. References herein to the Presentation shall mean and include this document, any oral presentation accompanying this do

  3. Slide 3: Adocia in Summary

    Slide 3: Adocia in Summary

    ADOCIA IN SUMMARY 1 2 3 4 5 Business model Clinical & $135M Licensing Global insulin Expansion to based on preclinical agreement ($50M supply adjacent innovative pipeline includes upfront) signed in agreement with indications formulation competitive 2018 with Tonghua THDB secures (Obesity, aiming to

  4. Slide 4: Delivering Personalized Treatments for People with Diabetes

    Slide 4: Delivering Personalized Treatments for People with Diabetes

    DELIVERING PERSONALIZED TREATMENTS FOR PEOPLE WITH DIABETES

  5. Slide 5: People with Diabetes Require More Personalized and More Physiologic Treatments

    Slide 5: People with Diabetes Require More Personalized and More Physiologic Treatments

    PEOPLE WITH DIABETES REQUIRE MORE PERSONALIZED AND MORE PHYSIOLOGIC TREATMENTS 425M1 people with Despite 100 years of medical treatment, long-term consequences of diabetes diabetes in 2017 26M2 remain a major issue. on insulin 79%3 live with severe 1 International Diabetes Federation Atlas, 2017 com

  6. Slide 6: People with Diabetes Have Different Profiles and Different Needs

    Slide 6: People with Diabetes Have Different Profiles and Different Needs

    PEOPLE WITH DIABETES HAVE DIFFERENT PROFILES AND DIFFERENT NEEDS « Diabetes » covers two types of disease, at different stages, with a range of complications, 90% T2D requiring a variety of treatments (10% T1D) Diabetes care is evolving towards more 65%1 drug/device integration and more diverse of U

  7. Slide 7: Adocia: Innovative Single & Bi-Hormonal Coformulations

    Slide 7: Adocia: Innovative Single & Bi-Hormonal Coformulations

    ADOCIA : INNOVATIVE SINGLE & BI-HORMONAL COFORMULATIONS FOR PERSONALIZED CARE OF DIABETES AND OBESITY Diabetes BC LISPRO & BC COMBO Adocia is committed to developing more efficient, easy-to-use treatments addressing the underlying complexity of diabetes Diabetes M1 PRAM ▪ Biobetters leveraging estab

  8. Slide 8: Differentiated Pipeline of Biobetters & Bi-Hormonal Formulations

    Slide 8: Differentiated Pipeline of Biobetters & Bi-Hormonal Formulations

    DIFFERENTIATED PIPELINE OF BIOBETTERS & BI-HORMONAL FORMULATIONS FOR THE TREATMENT OF DIABETES & METABOLIC DISEASES Preclinics Phase Phase Phase P C 1 2 3 BIOBETTERS BC Lispro U100 Diabetes BC Lispro U200 Diabetes BC Combo U200 Diabetes BC Glucagon Hypoglycemia BI-HORMONAL FORMULATIONS M1 PRAM Diabe

  9. Slide 9: Biobetters: BC Lispro, BC Combo, BC Glucagon

    Slide 9: Biobetters: BC Lispro, BC Combo, BC Glucagon

    BIOBETTERS: BC LISPRO, BC COMBO, BC GLUCAGON UNLOCKING THE POTENTIAL OF DIABETES TREATMENTS THROUGH SMART FORMULATION

  10. Slide 10: BioChaperone Lispro: Ultra-Rapid Insulin

    Slide 10: BioChaperone Lispro: Ultra-Rapid Insulin

    BIOCHAPERONE LISPRO ULTRA-RAPID INSULIN FOR TIGHTER POSTPRANDIAL GLYCEMIC CONTROL Post-meal glycaemia in T1D 9 trials in >250 people with T1D & T2D vs. Novolog, Humalog & Fiasp: ▪ Strong post-prandial glucose control AUC0-2h: ▪ Profile enabling dose-timing flexibility -61%* ▪ Potential for lower hyp

  11. Slide 11: BioChaperone Lispro

    Slide 11: BioChaperone Lispro

    BIOCHAPERONE LISPRO KEY ELEMENT TO ACHIEVE OPTIMIZED PERSONALIZED CARE IN DIABETES BioChaperone Lispro offers 3 key differentiating attributes: ▪ Dose timing flexibility in pens $7B ▪ Potential for high performance in Prandial insulin automated delivery systems market (2016)1 ▪ Concentrated U200 for

  12. Slide 12: BioChaperone Lispro: Next Steps for Worldwide Development

    Slide 12: BioChaperone Lispro: Next Steps for Worldwide Development

    BIOCHAPERONE LISPRO NEXT STEPS FOR WORLDWIDE DEVELOPMENT CHINA US/EU/Japan/RoW Partnered to Tonghua Dongbao Seeking partners on these territories Phase 3 start targeted 2020 Bridging study planned H1 2020 ▪ Milestone attached ▪ Comparability study BC Lispro (THDB insulin lispro) vs. BC Lispro (Humal

  13. Slide 13: BioChaperone Combo U200 (Glargine / Lispro)

    Slide 13: BioChaperone Combo U200 (Glargine / Lispro)

    BIOCHAPERONE COMBO U200 (GLARGINE / LISPRO) SAFER AND MORE EFFICIENT ALTERNATIVE TO PREMIX INSULIN Premix is used: BC Combo U200 presents: ▪ As 1st line insulin treatment in ▪ Stronger postprandial control and China lower risk of hypoglycemia vs. ▪ By elderly and T2D patients in Humalog® Mix25 in pe

  14. Slide 14: BioChaperone Glucagon

    Slide 14: BioChaperone Glucagon

    BIOCHAPERONE GLUCAGON READY-TO-USE SOLUTION FOR RESCUE FROM SEVERE HYPOGLYCEMIA 35%1 Plasma glucose Annual prevalence In a Phase 1 study in people with of severe hypo in T1D3, BC Glucagon (1mg) for rescue: T1D patients ▪ Was safe and well tolerated BioChaperone® Glucagon is a ready- ▪ Efficiently re

  15. Slide 15: Advanced Bi-Hormonal Coformulations

    Slide 15: Advanced Bi-Hormonal Coformulations

    ADVANCED BI-HORMONAL COFORMULATIONS DELIVERING GROUNDBREAKING OUTCOMES FOR PEOPLE WITH DIABETES

  16. Slide 16: Amylin: The Case of the Missing Hormone

    Slide 16: Amylin: The Case of the Missing Hormone

    AMYLIN THE CASE OF THE MISSING HORMONE In non-diabetic people, a time-sensitive hormonal pattern maintains normoglycemia. Prandial control involves both insulin and amylin. ADDING AMYLIN IN TANDEM WITH INSULIN IS KEY TO IMPROVING GLYCEMIC CONTROL AND OTHER METABOLIC AND NON-METABOLIC EFFECTS CORPORA

  17. Slide 17: M1 Pram: Coformulation of Insulin with Pramlintide

    Slide 17: M1 Pram: Coformulation of Insulin with Pramlintide

    M1 PRAM COFORMULATION OF INSULIN WITH PRAMLINTIDE (AMYLIN ANALOG ) Activates amylin receptors in different brain areas Unique Amylin multiple functions cannot ▪ Satiety be restored by algorithms driving ▪ Well-being automated insulin delivery systems ▪ Protects cognitive M1 PRAM combines prandial in

  18. Slide 18: M1 Pram: Next Generation Prandial Treatment

    Slide 18: M1 Pram: Next Generation Prandial Treatment

    M1 PRAM NEXT GENERATION PRANDIAL TREATMENT FOR HOLISTIC EFFECTS M1 PRAM leverages pramlintide’s In a study in 24 people with T1D1 demonstrated clinical benefits M1 PRAM (at mealtime) showed: « This combination has the ▪ 85% decrease in glycemic potential to finally deliver excursion in the first 2 h

  19. Slide 19: M1 Pram: Potential for Neuroprotective Effects

    Slide 19: M1 Pram: Potential for Neuroprotective Effects

    M1 PRAM POTENTIAL FOR NEUROPROTECTIVE EFFECTS IN T1D AND T2D Pramlintide’s use is associated with positive central nervous system effects ▪ Satiety 21%1 Of T1D ▪ “Well-being”2 27%1 Of T2D ▪ Alzheimer’s disease (AD) is correlated with report 70%3 accumulation of amyloid plaques and depressive Of T2D

  20. Slide 20: BioChaperone Glucagon GLP-1 Coformulation

    Slide 20: BioChaperone Glucagon GLP-1 Coformulation

    BIOCHAPERONE GLUCAGON GLP-1 COFORMULATION NEW GENERATION OF TREATMENT FOR DIABETES AND OBESITY Obesity is a key concern in the general population and for people with diabetes Body weight reduction 36.5%1 (14-day study in n=10 DIO mice) US adults Based on BC Glucagon, Adocia develops an are obese inj

  21. Slide 21: Chinese Partnership Supports Adocia Growth

    Slide 21: Chinese Partnership Supports Adocia Growth

    CHINESE PARTNERSHIP SUPPORTS ADOCIA GROWTH LICENSING & SUPPLY AGREEMENTS WITH TONGHUA DONGBAO

  22. Slide 22: China Is "The Place to Be"

    Slide 22: China Is "The Place to Be"

    CHINA IS « THE PLACE TO BE »… ESPECIALLY IN DIABETES The Chinese insulin market is vast and remains 1.4 underserved. Its growth is driven by multiple factors: ▪ Better diagnosis billion Chinese ▪ Better reimbursement population 2018 10.9% ▪ Increasing medical access to remote areas Diabetes 65% prev

  23. Slide 23: Tonghua Dongbao Is the Right Partner

    Slide 23: Tonghua Dongbao Is the Right Partner

    … AND TONGHUA DONGBAO IS THE RIGHT PARTNER $4.4 Bn Market cap (Nov 2019) 25%1 YOY revenue growth 26%2 Share of Chinese human insulin 78%1 market Of revenue from insulin 1 Data THDB 2 IQVIA, volume, 2018 CORPORATE PRESENTATION – JANUARY 2020 • 23

  24. Slide 24: Adocia and THDB Entered Strategic Alliance

    Slide 24: Adocia and THDB Entered Strategic Alliance

    ADOCIA AND THDB ENTERED STRATEGIC ALLIANCE TO DEVELOP BEST-IN-CLASS INSULINS In April 2018, Adocia and Tonghua Dongbao announced a strategic partnership to develop and $50M +$85M commercialize BC Combo & BC Lispro in China and Upfront (development other Asian and Middle East territories milestones)

  25. Slide 25: Strategic Supply Agreements with Tonghua Dongbao

    Slide 25: Strategic Supply Agreements with Tonghua Dongbao

    STRATEGIC SUPPLY AGREEMENTS WITH TONGHUA DONGBAO OPEN GLOBAL OPPORTUNITIES FOR ADOCIA With access to stable, high-quality insulin lispro and insulin glargine supply, Adocia can out-license and commercialize BC Lispro and BC Combo, notably in the US, EU and Japan Partnering opportunities are multipli

  26. Slide 26: Financial Overview

    Slide 26: Financial Overview

    FINANCIAL OVERVIEW ADOCIA innovative medicine for everyone, everywhere

  27. Slide 27: Key Financial Elements

    Slide 27: Key Financial Elements

    KEY FINANCIAL ELEMENTS Financial Summary Shareholders’ equity (Dec 2019) Analysts Kepler Market Listed on Euronext Paris (ADOC) Free Float Soula Family 22,1 % Arsène Guekam 59.1% ▪ 6.9M shares outstanding Oddo ▪ ADR program in the US (ADOCY) Oussama Denguir €85M raised since inception HC Wainwright

  28. Slide 28: Expected Newsflow

    Slide 28: Expected Newsflow

    EXPECTED NEWSFLOW ADOCIA innovative medicine for everyone, everywhere

  29. Slide 29: Upcoming Newsflow

    Slide 29: Upcoming Newsflow

    UPCOMING NEWSFLOW MULTIPLE MILESTONES EXPECTED IN 2020 BI-HORMONAL BIOBETTERS BUSINESS COFORMULATIONS BC LISPRO M1PRAM BC LISPRO & BC COMBO ▪ China (THDB): Phase 3 start expected ▪ Results from second Phase 1/2 trial ▪ Looking to partner in in 2020 expected Q1 2020 US/EU/Japan/LatAm/Oceania ▪ US/EU/

  30. Slide 30: Conclusion

    Slide 30: Conclusion

    CONCLUSION 1 CHINA: A TARGET MARKET Strategic partnership with Tonghua Dongbao opens Chinese and international markets 2 A PIPELINE AT THE FOREFRONT OF DIABETES AND METABOLIC DISEASE CHALLENGES BC Lispro displays a very promising profile in the context of personalized and integrated diabetes care (p

  31. Slide 31: Notes

    Slide 31: Notes

    NOTES CORPORATE PRESENTATION – JANUARY 2020 • 31

  32. Slide 32: Thank You for Your Kind Interest

    Slide 32: Thank You for Your Kind Interest

    THANK YOU FOR YOUR KIND INTEREST ADOCIA 115 avenue Lacassagne 69003 Lyon – France Tel +33 4 72 610 610 contact@adocia.com

Source: Internet Archive copy of adocia.com

More decks from Adocia SA

All 49 Adocia SA decks